Tech Company Financing Transactions

Novome Biotechnologies Funding Round

Novome Biotechnologies, operating out of San Francisco, raised $43.5 million from Tencent Holdings, 5AM Ventures and Alexandria Venture Investments.

Transaction Overview

Company Name
Novome Biotechnologies
Announced On
9/13/2022
Transaction Type
Venture Equity
Amount
$43,500,000
Round
Series B
Investors

Tencent Holdings (Lead Investor)

5AM Ventures (Andrew Schwab)

Alexandria Venture Investments

Alta Partners (Daniel Janney)

Colorcon Ventures

DCVC Bio

Navian Capital

Touchdown Ventures

University of Minnesota

Proceeds Purpose
The proceeds will be used to advance both Novome's clinical hyperoxaluria candidate, NOV-001, through an ongoing Phase 2a clinical trial and multiple Genetically Engineered Microbial Medicines (GEMMs) candidates for the potential treatment of inflammatory bowel disease (IBD); candidates are either fully owned by Novome or part of a previously announced collaboration with Genentech.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
279 E Grand Ave. 420
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
www.novomebio.com
Email Address
[email protected]
Overview
Novome Biotechnologies is engineering bacteria from the human gut to treat diseases. Based on pioneering technology developed at Stanford University, we bring together experts in the fields of synthetic biology and the microbiome to build novel cell-based therapies.
Profile
Novome Biotechnologies LinkedIn Company Profile
Social Media
Novome Biotechnologies Company Twitter Account
Company News
Novome Biotechnologies News
Facebook
Novome Biotechnologies on Facebook
YouTube
Novome Biotechnologies on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Blake Wise
  Blake Wise LinkedIn Profile  Blake Wise Twitter Account  Blake Wise News  Blake Wise on Facebook
Chief Scientific Officer
William DeLoache
  William DeLoache LinkedIn Profile  William DeLoache Twitter Account  William DeLoache News  William DeLoache on Facebook
Co-Founder
Zachary Russ
  Zachary Russ LinkedIn Profile  Zachary Russ Twitter Account  Zachary Russ News  Zachary Russ on Facebook
Co-Founder
Elizabeth Shepherd
  Elizabeth Shepherd LinkedIn Profile  Elizabeth Shepherd Twitter Account  Elizabeth Shepherd News  Elizabeth Shepherd on Facebook
Controller
Shu Kurosaki
  Shu Kurosaki LinkedIn Profile  Shu Kurosaki Twitter Account  Shu Kurosaki News  Shu Kurosaki on Facebook
VP - Bus. Development
Lane Weaver
  Lane Weaver LinkedIn Profile  Lane Weaver Twitter Account  Lane Weaver News  Lane Weaver on Facebook
VP - R & D
Weston Whitaker
  Weston Whitaker LinkedIn Profile  Weston Whitaker Twitter Account  Weston Whitaker News  Weston Whitaker on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/13/2022: GrowerIQ venture capital transaction
Next: 9/13/2022: RapidPulse venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.